Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Trazodone Hydrochloride | AF-1161; DDS-04A | Approved | Pragma Pharmaceuticals Llc | Molipaxin, Trittico, Desyrel, Oleptro | Mainland China | Depression | Lotus Pharmaceutical Co Ltd | 1981-12-24 | Sleep Initiation and Maintenance Disorders; Depressive Disorder, Major; Depression; Opioid-Related Disorders; Diabetic Neuropathies; Anxiety Disorders; Premature Ejaculation; Sleep Wake Disorders; Sleep Apnea, Obstructive; Hypertension; Alzheimer Disease; Cognitive Dysfunction; Alcoholism; Dyssomnias; Sleep; Kidney Failure, Chronic | Details |
| Aripiprazole Lauroxil | RDC-3317; ALKS-9070; ALKS-9072 | Approved | Alkermes Plc | Aristada | United States | Schizophrenia | Alkermes Inc | 2015-10-05 | Schizophrenia; Psychotic Disorders; Bipolar Disorder; Behavioral Symptoms; Autistic Disorder | Details |
| Brexpiprazole | Lu-AF41156; OPDC-34712; OPC-34712; OPC-34712 FUM | Approved | Otsuka Pharmaceutical Co Ltd | Rxulti, Rexulti, REXULTIOD, RexultiOD | United States | Depressive Disorder, Major; Schizophrenia | Otsuka Pharmaceutical Co Ltd | 2015-07-10 | Autistic Disorder; Conduct Disorder; Mental Disorders; Borderline Personality Disorder; Attention Deficit and Disruptive Behavior Disorders; Performance Anxiety; Irritable Mood; Nervous System Diseases; Alcoholism; Stress Disorders, Post-Traumatic; Alzheimer Disease; Depressive Disorder; Schizophrenia; Bipolar I Disorder; Sleep Wake Disorders; Bipolar Disorder; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Agitation; Anxiety; Mood Disorders; Depressive Disorder, Major; Depression | Details |
| Flibanserin | BIMT-17; BIMT-17-BS | Approved | Sprout Pharmaceuticals Inc | Addyi, Girosa | United States | Sexual Dysfunctions, Psychological | Sprout Pharmaceuticals Inc | 2015-08-18 | Depression; Prostatic Neoplasms; Sexual Dysfunctions, Psychological | Details |
| Alverine Citrate | Approved | Spasmaverine | Irritable Bowel Syndrome; Dysmenorrhea | Details | ||||||
| Cinitapride Tartrate | LAS-17177 | Approved | Almirall Sa | Blaston, Cinigest, Cidine, Pemix, 希笛尼 | Spain | Gastroesophageal Reflux; Gastroparesis | null | 1990-01-01 | Dyspepsia; Gastroparesis; Gastroesophageal Reflux | Details |
| Lisuride Maleate | Approved | Dopergin, Nenad | Parkinson Disease; Cocaine-Related Disorders | Details | ||||||
| Cinitapride Tartrate/Omeprazole | Approved | Zydus Cadila | Burpex | India | Gastroesophageal Reflux; Dyspepsia; Stomach Ulcer | Zydus Cadila | 2010-01-01 | Dyspepsia; Stomach Ulcer; Gastroesophageal Reflux | Details | |
| Cariprazine Hydrochloride | RGH-188; RGH-188 HCl; MP-214; WID-RGC20 | Approved | Gedeon Richter, Abbvie Inc | Vraylar, Reagila | United States | Bipolar Disorder; Schizophrenia | Abbvie Inc | 2015-09-17 | Schizophrenia; Depression; Depressive Disorder, Major; Autism Spectrum Disorder; Bipolar Disorder; Opioid-Related Disorders; Anxiety Disorders; Bipolar I Disorder; Cocaine-Related Disorders | Details |
| Vilazodone Hydrochloride | EMD-68843; EMD-515259; SB-659746A | Approved | Forest Laboratories Inc | Viibryd | United States | Depressive Disorder, Major | Abbvie Inc | 2011-01-21 | Depressive Disorder, Major; Depression; Marijuana Abuse; Anxiety Disorders; Depressive Disorder; Stress Disorders, Post-Traumatic; Memory Disorders | Details |
| Zolmitriptan | BW-311C90; 311-C-90; 311C; 311-C90; M-207 | Approved | Astrazeneca Plc | Zolmitriptan RapidFilm, Flezol, Zomig, Zomigon, 佐米格, AscoTop | United Kingdom | Migraine Disorders | null | 1997-03-01 | Migraine Disorders | Details |
| Aripiprazole | BMS-337039; OPC-14597; OPC-31; OPC-14597-IMD | Approved | Otsuka Holdings Co Ltd | Abilify Asimtufii, Arlemide, Asimtufii, Abilify Discmelt, Abilify OD, Abilitat, Abilify, Abilify Maintena | United States | Irritable Mood; Bipolar Disorder; Depressive Disorder, Major; Tic Disorders; Autistic Disorder; Schizophrenia | Otsuka Holdings Co Ltd | 2002-11-15 | Alzheimer Disease; Dermatitis; Bipolar I Disorder; Tourette Syndrome; Depressive Disorder; Fragile X Syndrome; Depressive Disorder, Treatment-Resistant; Alcoholism; Stress Disorders, Post-Traumatic; Emergence Delirium; Dementia; Asperger Syndrome; Nervous System Diseases; Irritable Mood; Cocaine-Related Disorders; Trichotillomania; Mental Disorders; Psychotic Disorders; Substance-Related Disorders; HIV Infections; Schizophrenia; Depressive Disorder, Major; Depression; Autism Spectrum Disorder; Depression, Postpartum; Attention Deficit Disorder with Hyperactivity; Developmental Disabilities; Bipolar Disorder; Body Weight Changes; Metabolic Syndrome; Opioid-Related Disorders; Behavioral Symptoms; Tic Disorders; Autistic Disorder | Details |
| Tandospirone citrate | AL-8309B; AL-8309A; AL-8309; SM-3997 | Approved | 希德, Sediel | Japan | Sleep Wake Disorders; Phobic Disorders; Depression; Neurotic Disorders | Dainippon Sumitomo Pharma Co Ltd | 1996-07-10 | Depression; Anxiety; Sleep Wake Disorders; Geographic Atrophy; Phobic Disorders; Neurotic Disorders; Macular Degeneration | Details | |
| Buspirone Hydrochloride | MJ-9022-1; APC-6003 (oral); APC-6002 (topical) | Approved | Bristol-Myers Squibb Company | Buspimen, Narol, Bespar, BuSpar | Mainland China | Anxiety Disorders | Pku Healthcare Corp Ltd | Autistic Disorder; Opium Dependence; Postoperative Complications; Cocaine-Related Disorders; Movement Disorders; Epilepsy; Substance Withdrawal Syndrome; Parkinson Disease; Quadriplegia; Dependency, Psychological; Anhedonia; Dyskinesias; Dyspnea; Gastroparesis; Solid tumours; Opioid-Related Disorders; Anxiety Disorders; Vertigo; Epilepsies, Partial; Mood Disorders; Chronic Pain; Anxiety; Marijuana Abuse; Schizophrenia; Seizures; Depression; Spinal Cord Injuries; Primary Dysautonomias | Details | |
| Lurasidone Hydrochloride | MK-3756; SMP-13496; SM-13496 | Approved | Sumitomo Dainippon | 罗舒达, Latuda | United States | Schizophrenia | Sunovion Pharmaceuticals Inc | 2010-10-28 | Schizophrenia; Depressive Disorder, Major; Depression; Bipolar Disorder; Psychotic Disorders; Autistic Disorder; Bipolar I Disorder; Depressive Disorder; Child Development Disorders, Pervasive; Bipolar II Disorder; Asperger Syndrome | Details |
| Vortioxetine Hydrobromide | LuAA-21004; Lu-AA21004; KH-709 | Approved | Takeda Pharmaceutical Co Ltd | Brintellix, Trintellix, Brintellix/Trintellix | United States | Depressive Disorder, Major | Takeda Pharmaceuticals USA Inc | 2013-09-30 | Binge-Eating Disorder; Brain Injuries, Traumatic; Depressive Disorder, Major; Depression; Marijuana Abuse; Anxiety; Coronary Artery Disease; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Pain, Postoperative; Liver Diseases; Frontotemporal Lobar Degeneration; Radiation Injuries; Depressive Disorder; Frontotemporal Dementia | Details |
| Alverine Citrate /Dimethicone | Approved | Flatulence; Gastroenteritis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ulotaront | SEP-363856; SEP-856 | Phase 3 Clinical | Sumitomo Dainippon Pharma Co Ltd | Schizophrenia; Depressive Disorder, Major; Anxiety Disorders; Parkinson Disease; Narcolepsy | Details |
| Brilaroxazine | RP-5000; RP-5063 | Phase 3 Clinical | Reviva Pharmaceuticals Inc | Depressive Disorder, Major; Schizophrenia; Bipolar Disorder; Idiopathic Pulmonary Fibrosis; Attention Deficit Disorder with Hyperactivity; Psoriasis; Pulmonary Arterial Hypertension | Details |
| Piromelatine | Neu-P11 | Phase 3 Clinical | Neurim Pharmaceuticals Ltd | Sleep Initiation and Maintenance Disorders; Glaucoma, Open-Angle; Alzheimer Disease | Details |
| Espindolol | MT-102; AGI-001; ACM-001.1; ACM-001 | Phase 3 Clinical | Akamis Bio Ltd, Actimed Therapeutics Ltd | Colorectal Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung | Details |
| Psilocybin | MYCO-001; TRP-8804; TRYP-0082; TRP-8802; TRP-8803; COMP-360 | Phase 3 Clinical | TRYP Therapeutics Inc | Parkinson Disease; Healthy Aging; Cognitive Dysfunction; Amphetamine-Related Disorders; Alzheimer Disease; Bipolar II Disorder; Alcoholism; Depressive Disorder, Treatment-Resistant; Stress Disorders, Post-Traumatic; Lymphoma; Mental Health; Osteosarcoma; Breast Neoplasms; Post-Concussion Syndrome; Tobacco Use Disorder; Depressive Disorder; Demoralization; Obsessive-Compulsive Disorder; Gastrointestinal Neoplasms; Post-Traumatic Headache; Sleep; Low Back Pain; Stress Disorders, Traumatic; Anorexia Nervosa; Melanoma; Mental Disorders; Fibromyalgia; Psychotherapy, Group; Cluster Headache; Amyotrophic Lateral Sclerosis; Amnesia; Psychological Distress; Borderline Personality Disorder; Cocaine-Related Disorders; Pulmonary Disease, Chronic Obstructive; Binge-Eating Disorder; Pain; Anxiety; Post-Lyme Disease Syndrome; Marijuana Abuse; Depression; Depressive Disorder, Major; Body Dysmorphic Disorders; Endocrine Gland Neoplasms; Mood Disorders; Acrodynia; Biliary Tract Neoplasms; Ovarian Neoplasms; Migraine Disorders; | Details |
| Deuterated psilocybin analog | CYB-003 | Phase 3 Clinical | Cybin Inc | Depressive Disorder, Major | Details |
| Cariprazine hydrochloride (Chengdu Kanghong Pharmaceutical) | KH-734 | Phase 3 Clinical | Chengdu Kanghong Pharmaceutical Group Co Ltd | Schizophrenia | Details |
| SF-001 | SF-001; SF001 | Phase 3 Clinical | Seasons Biotechnology (Taizhou) Co Ltd | HIV Infections; Meningitis, Cryptococcal; Depressive Disorder | Details |
| Psilocybin（Pilz Bioscience） | NM-1001; NM-1010; PLZ-1013 | Phase 3 Clinical | Pilz Bioscience Corp | Behavior; Fragile X Syndrome; Cognitive Dysfunction; Depressive Disorder, Treatment-Resistant | Details |
| Lurasidone/Cycloserine | NRX-101 | Phase 3 Clinical | Neurorx, Avineuro | Suicide, Attempted; Anxiety; Depression; Pain; Self-Injurious Behavior; Smoking Cessation; Bipolar Disorder; Harm Reduction; Suicidal Ideation; Urinary Tract Infections; Pyelonephritis; Low Back Pain | Details |
| TGBA01AD | FKB01MD; TGBA01AD; TGBA-01AD | Phase 2 Clinical | Fabre-Kramer | Depressive Disorder, Major | Details |
| AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Psoriasis; Dermatitis, Atopic; Vitiligo | Details |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | Details |
| Buspirone/Carbidopa/Levodopa | Phase 2 Clinical | Universite Laval | Spinal Cord Injuries; Multiple Sclerosis | Details | |
| TGW00AA | FKW00GA; TGW00AA; TGWOOAA; TGW00AA-HCl; TGWOOAA-HCl | Phase 2 Clinical | Fabre-Kramer | Anxiety; Phobia, Social | Details |
| Psilocybin (Filament Health) | PEX-010; PEX010; PEX-020; PEX-030; PLZ-1015 | Phase 2 Clinical | Filament Health Corp | Substance-Related Disorders; Depression; Depressive Disorder, Major; Chronic Pain; Opioid-Related Disorders; Depressive Disorder; Obsessive-Compulsive Disorder; Alcoholism; Mental Disorders | Details |
| VLS-01 | BMND-07; DMA; AP-188; DMT; VLS-01; BMND-01; BMND01; BMND07 | Phase 2 Clinical | Algernon Pharmaceuticals Inc, Biomind Labs Inc | Depressive Disorder, Major; Stroke; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Mental Disorders | Details |
| Quetiapine (Qrono) | QR-103 | Phase 2 Clinical | Qrono Inc | Sleep Apnea, Obstructive; Renal Insufficiency, Chronic; Mental Disorders | Details |
| S-oxprenolol | ACM-002; FDY 8801 | Phase 2 Clinical | Actimed Therapeutics Ltd | Cachexia; Amyotrophic Lateral Sclerosis | Details |
| Psilocybin (GoodMind Therapeutics) | Phase 2 Clinical | GoodMind Therapeutics Pty Ltd | Depressive Disorder, Treatment-Resistant | Details | |
| Synthetic psilocybin(Ceruvia Lifesciences) | SYNP-101 | Phase 2 Clinical | Ceruvia Lifesciences | Obsessive-Compulsive Disorder; Alcoholism; Headache Disorders | Details |
| Befiradol Fumarate | NLX-112; F-13640 | Phase 2 Clinical | Pierre Fabre Group | Dyskinesias | Details |
| Psilocybin (Revive Therapeutics) | PSY-0.1; PSY-0.2; PSY-0.4/0.5; PSY-0.3; PSY-0.6 | Phase 2 Clinical | Psilocin Pharma Corp | Substance-Related Disorders; Depression; Anxiety; Chemically-Induced Disorders | Details |
| Nature-derived psilocybin(Psyence Biomed) | Phase 2 Clinical | Psyence Biomedical Ltd | Neoplasms | Details | |
| Nature-derived psilocybin(Psyence Biomedical) | Phase 2 Clinical | Psyence Group Inc | Neoplasms | Details | |
| Psilocybin(Incannex) | PSX-001 | Phase 2 Clinical | Incannex Healthcare Ltd | Anxiety Disorders | Details |
| WP-001 | WP001; WP-001 | Phase 2 Clinical | Macquarie University, Woke Pharmaceuticals Pty Ltd | Depressive Disorder | Details |
| Psilocybin(Apex Laboratories) | APEX-90 | Phase 2 Clinical | Apex Laboratories LLC | Depressive Disorder, Treatment-Resistant | Details |
| Psilocybin infusion (Beckley Psytech) | ELE-Psilo; ELE-Psilo+; ELE-101 | Phase 2 Clinical | Eleusis Holdings Ltd | Depression; Depressive Disorder, Major | Details |
| Mebufotenin (Beckley Psytech) | BPL-003; 5-MeO-DMT (Beckley Psytech); BPL-002 | Phase 2 Clinical | Depressive Disorder, Treatment-Resistant; Alcoholism | Details | |
| HS-10380 | HS-10380; HS10380 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Schizophrenia; Bipolar Disorder; Alzheimer Disease | Details |
| Mebufotenin | 5-MeO-DMT; GH-001; GH-002; GH-003 | Phase 2 Clinical | GH Research Ireland Ltd | Depressive Disorder, Major; Depression; Depression, Postpartum; Bipolar II Disorder; Depressive Disorder, Treatment-Resistant | Details |
| SIPI-6398 | SIPI-6398; SIPI6398; ZZ-6398 | Phase 2 Clinical | Shanghai Zhongze Pharmaceutical Technology Co Ltd | Schizophrenia; Depressive Disorder | Details |
| Hypidone Hydrochloride | YL-0919 | Phase 2 Clinical | Zhejiang Huahai Pharmaceutical Co Ltd, Institute Of Toxicants And Drugs, Academy Of Military Medical Sciences, Chinese People'S Liberation Army | Depression; Depressive Disorder, Major | Details |
| TPN-672 Maleate | TPN-672; TPN-672 Maleate | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Schizophrenia | Details |
| F-15599 | F-15599; NLX-101 | Phase 1 Clinical | Pierre Fabre Ltd | Schizophrenia; Rett Syndrome; Mood Disorders; Cognition Disorders | Details |
| NH-305 | NH-305 | Phase 1 Clinical | Jiangsu Nhwa Pharmaceutical Co Ltd | Cognition Disorders | Details |
| CYB-004 (Cybin) | Phase 1 Clinical | Cybin Inc | Anxiety Disorders | Details | |
| aripiprazole (Livzon Microsphere Technology) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Schizophrenia; Dissociative Identity Disorder | Details | |
| Psilocybin (MycoMedia Life Sciences) | MLS-101 (MycoMedia Life Sciences); MLS101 (MycoMedia Life Sciences) | Phase 1 Clinical | MycoMedica Life Sciences PBC | Details | |
| DSP-0038 | DSP-0038 | Phase 1 Clinical | Sumitomo Chemical Co Ltd, Exscientia Ltd | Alzheimer Disease | Details |
| Synthetic psilocybin(Sheppard Pratt) | Phase 1 Clinical | Sheppard Pratt | Bipolar Disorder | Details | |
| DSP-9632P | DSP-9632P; DD701102 | Phase 1 Clinical | Sumitomo Dainippon Pharma Co Ltd | Levodopa-induced dyskinesia; Parkinson Disease | Details |
| SKL-PSY | FZ-016; SKL-PSY; SKL-PSY/FZ-016 | Phase 1 Clinical | SK Biopharmaceuticals Co Ltd | Depression | Details |
| REC-0545 | REC-0545 | Clinical | Recordati Spa | Urinary Bladder, Overactive | Details |
| MP-20X | MP-20X | Clinical | Medipure Holdings | Mood Disorders; Anxiety Disorders | Details |
| Psilocybin (Diamond Therapeutics) | Clinical | Diamond Therapeutics Inc | Mental Disorders | Details | |
| ACH-000029 | ACH000029 | Ache Laboratories | Details | ||
| Psilocybin trihydrate(Johns Hopkins University) | Johns Hopkins University, Private Philanthropic Funds | Details |
This web search service is supported by Google Inc.
A-Z
